CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Corona Remedies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Corona Remedies Ltd
Phone: +91 7940233000p:+91 7940233000 AHMEDABAD, 380059  India Ticker: CORONACORONA
Business Summary
Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20253/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Managing Director (Promoter) Niravkumar K.Mehta 48 8/27/2024 5/30/2007
Chief Financial Officer Bhavin N.Bhagat 10/24/2024 10/24/2024
Whole-Time Director Viral B.Sitwala 47 1/1/2010 1/1/2010
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 4,573 (As of 6/30/2025)
Outstanding Shares: 61,160,088 (As of 6/30/2025)
Stock Exchange: NSE
Fax Number: +91 7940233999


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, December 17, 2025